PMID- 28732279
OWN - NLM
STAT- MEDLINE
DCOM- 20180521
LR  - 20181113
IS  - 1879-0372 (Electronic)
IS  - 0952-7915 (Print)
IS  - 0952-7915 (Linking)
VI  - 47
DP  - 2017 Aug
TI  - Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic 
      cancer vaccines.
PG  - 35-43
LID - S0952-7915(17)30012-2 [pii]
LID - 10.1016/j.coi.2017.06.003 [doi]
AB  - Development of therapeutic cancer vaccines has been hindered by the many 
      pro-tumorigenic mechanisms at play in cancer patients that serve to suppress both 
      antigen presenting cells and T cells. In face of these obstacles, cancer vaccines 
      are most likely to promote anti-tumorigenic immune responses only when formulated 
      with strong adjuvants, and in combination with new immune interventions designed 
      to reverse immune suppression and exhaustion of T cells in the tumor 
      microenvironment. Dendritic cells (DCs) are often termed 'nature's adjuvant' due 
      to their exceptional capacity for initiating both innate and adaptive immune 
      responses. Hence, the past decade has witnessed a flurry of activity in testing 
      DC based immunotherapies for cancer intervention. In this review we will discuss 
      advances in conventional adjuvants and provide insight into new adjuvants as they 
      pertain to DC cancer therapy.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Saxena, Mansi
AU  - Saxena M
AD  - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York 
      City, NY 10029, USA.
FAU - Bhardwaj, Nina
AU  - Bhardwaj N
AD  - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York 
      City, NY 10029, USA; Parker Institute of Cancer Immunotherapy, USA. Electronic 
      address: nina.bhardwaj@mssm.edu.
LA  - eng
GR  - R01 AI081848/AI/NIAID NIH HHS/United States
GR  - R01 CA180913/CA/NCI NIH HHS/United States
GR  - R01 CA201189/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170718
PL  - England
TA  - Curr Opin Immunol
JT  - Current opinion in immunology
JID - 8900118
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Antigen Presentation
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology/transplantation
MH  - Humans
MH  - Immunity, Humoral
MH  - Immunotherapy, Adoptive/*methods
MH  - Lymphocyte Activation
MH  - Neoplasms/immunology/*therapy
MH  - Tumor Microenvironment
PMC - PMC5626599
MID - NIHMS891167
EDAT- 2017/07/22 06:00
MHDA- 2018/05/22 06:00
PMCR- 2018/08/01
CRDT- 2017/07/22 06:00
PHST- 2017/04/07 00:00 [received]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/07/22 06:00 [pubmed]
PHST- 2018/05/22 06:00 [medline]
PHST- 2017/07/22 06:00 [entrez]
PHST- 2018/08/01 00:00 [pmc-release]
AID - S0952-7915(17)30012-2 [pii]
AID - 10.1016/j.coi.2017.06.003 [doi]
PST - ppublish
SO  - Curr Opin Immunol. 2017 Aug;47:35-43. doi: 10.1016/j.coi.2017.06.003. Epub 2017 
      Jul 18.